Tarsus posts acquisition-driven Q3 loss and raises XDEMVY outlook
+2 new sources since this summary was written
Tarsus Pharmaceuticals reported a third-quarter 2026 net loss of $668.3 million, or $14.40 per share, after recording $632.2 million in acquired in-process research and development costs. XDEMVY net product sales increased approximately 64% year over year to $194.6 million from $118.7 million. The company raised its 2026 XDEMVY sales forecast to between $715 million and $730 million and expects gross margin of approximately 93%.
Why it matters
XDEMVY growth and the higher full-year sales outlook improve the commercial outlook, while acquisition-related charges sharply reduce reported earnings for the quarter. The updated forecast changes the revenue expectations investors will use for 2026, while pipeline trials remain important future catalysts.
Key facts
- 1Third-quarter net product sales rose approximately 64% to $194.6 million from $118.7 million in the year-earlier quarter. rttnews.com
- 2Tarsus recorded a net loss of $668.3 million, or $14.40 per share, compared with a $12.6 million loss, or $0.30 per share, in the prior-year quarter. rttnews.com
- 3The company increased its 2026 XDEMVY sales outlook to between $715 million and $730 million. finance.yahoo.com
- 4Tarsus expects 2026 gross margin to remain at approximately 93%. finance.yahoo.com
- 5The company reported $309.6 million in cash, cash equivalents and marketable securities at September 30, 2026. rttnews.com
- 6Approximately 20% of third-quarter prescriptions were refills, according to the company. rttnews.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.